{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:50:30Z","timestamp":1768726230779,"version":"3.49.0"},"reference-count":101,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T00:00:00Z","timestamp":1713225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Multiple myeloma (MM) is an incurable malignant plasma cell disorder characterized by the infiltration of clonal plasma cells in the bone marrow compartment. Gene Expression Profiling (GEP) has emerged as a powerful investigation tool in modern myeloma research enabling the dissection of the molecular background of MM and allowing the identification of gene products that could potentially serve as targets for therapeutic intervention. In this study we investigated shared transcriptomic abnormalities across newly diagnosed multiple myeloma (NDMM) patient cohorts. In total, publicly available transcriptomic data of 7 studies from CD138+ cells from 281 NDMM patients and 44 healthy individuals were integrated and analyzed. Overall, we identified 28 genes that were consistently differentially expressed (DE) between NDMM patients and healthy donors (HD) across various studies. Of those, 9 genes were over\/under-expressed in more than 75% of NDMM patients. In addition, we identified 4 genes (MT1F, PURPL, LINC01239 and LINC01480) that were not previously considered to participate in MM pathogenesis. Meanwhile, by mining three drug databases (ChEMBL, IUPHAR\/BPS and DrugBank) we identified 31 FDA-approved and 144 experimental drugs that target 8 of these 28 over\/under-expressed MM genes. Taken together, our study offers new insights in MM pathogenesis and importantly, it reveals potential new treatment options that need to be further investigated in future studies.<\/jats:p>","DOI":"10.3389\/fonc.2024.1390105","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:00:56Z","timestamp":1713243656000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["A comparative analysis of transcriptomics of newly diagnosed multiple myeloma: exploring drug repurposing"],"prefix":"10.3389","volume":"14","author":[{"given":"Angelos","family":"Giannakoulas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marios","family":"Nikolaidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grigorios D.","family":"Amoutzias","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Giannakoulas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2020-0141","article-title":"Multiple myeloma incidence and mortality around the globe; interrelations between health access and quality, economic resources, and patient empowerment","volume":"25","author":"Ludwig","year":"2020","journal-title":"Oncologist"},{"key":"B2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/ijc.22718","article-title":"Multiple myeloma: a review of the epidemiologic literature","volume":"12","author":"Alexander","year":"2007","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709974","article-title":"Long-term follow-up of monoclonal gammopathy of undetermined significance","volume":"378","author":"Kyle","year":"2018","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am J Hematol"},{"key":"B6","unstructured":"2023"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s12885-023-10787-5","article-title":"Time trends in survival and causes of death in multiple myeloma: a population-based study from Germany","volume":"23","author":"Eisfeld","year":"2023","journal-title":"BMC Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458","article-title":"The molecular classification of multiple myeloma","volume":"108","author":"Zhan","year":"2006","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.174","article-title":"International Myeloma Working Group molecular classification of multiple myeloma: spotlight review","volume":"23","author":"Fonseca","year":"2009","journal-title":"Leukemia"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261032","article-title":"Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients","volume":"116","author":"Broyl","year":"2010","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.127","article-title":"A gene expression signature for high-risk multiple myeloma","volume":"26","author":"Kuiper","year":"2012","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","first-page":"5450","DOI":"10.1038\/s41467-021-25704-2","article-title":"Chromatin-based, in cis and in trans regulatory rewiring underpins distinct oncogenic transcriptomes in multiple myeloma","volume":"12","author":"Alvarez-Benayas","year":"2021","journal-title":"Nat Commun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009754","article-title":"Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development","volume":"138","author":"Alameda","year":"2021","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.201301","article-title":"Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma","volume":"104","author":"Taiana","year":"2019","journal-title":"Hematologica"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404520","article-title":"Gene expression profiling of B lymphocytes and plasma cells from Waldenstr\u00f6m\u2019s macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals","volume":"21","author":"Guti\u00e9rrez","year":"2007","journal-title":"Leukemia"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.087809","article-title":"Transcriptome analysis reveals molecular profiles associated with evolving steps of monoclonal gammopathies","volume":"99","author":"L\u00f3pez-Corral","year":"2014","journal-title":"Haematologica"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-4046","article-title":"Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling","volume":"67","author":"Chng","year":"2007","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.274","article-title":"Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling","volume":"24","author":"Guti\u00e9rrez","year":"2010","journal-title":"Leukemia"},{"key":"B20","unstructured":"2023"},{"key":"B21","unstructured":"Babraham bioinformatics"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"key":"B23","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gks1193","article-title":"NCBI GEO: archive for functional genomics data sets\u2013update","volume":"41","author":"Barrett","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkac888","article-title":"Genenames.org: the HGNC resources in 2023","volume-title":"Nucleic Acids Res","author":"Seal","year":"2023"},{"key":"B28","doi-asserted-by":"publisher","first-page":"R25","DOI":"10.1186\/gb-2010-11-3-r25","article-title":"A scaling normalization method for differential expression analysis of RNA-seq data","volume":"11","author":"Robinson","year":"2010","journal-title":"Genome Biol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081793","article-title":"Role and therapeutic targeting of SDF-1\u03b1\/CXCR4 axis in multiple myeloma","volume":"13","author":"Ito","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/1873-3468.13623","article-title":"Single-cell RNA sequencing reveals chemokine self-feeding of myeloma cells promotes extramedullary metastasis","volume":"594","author":"Geng","year":"2020","journal-title":"FEBS Lett"},{"key":"B31","article-title":"[Expression of vascular cell adhesion molecule-1 in patients with multiple myeloma and its significance]","volume":"17","author":"Liu","year":"2009","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03792.x","article-title":"CD106 and activated-CD29 are expressed on myelomatous bone marrow plasma cells and their downregulation is associated with tumor progression","volume":"119","author":"Luque","year":"2002","journal-title":"Br J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0787","article-title":"Targeting the RB-pathway in cancer therapy","volume":"16","author":"Knudsen","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402875","article-title":"The hepatocyte growth factor\/Met pathway controls proliferation and apoptosis in multiple myeloma","volume":"17","author":"Derksen","year":"2003","journal-title":"Leukemia"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611083","article-title":"LAMP5 may promote MM progression by activating p38","volume":"29","author":"Chen","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3546","article-title":"Endothelin 1 in cancer: biological implications and therapeutic opportunities","volume":"13","author":"Rosan\u00f2","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2020.05.140","article-title":"DUSP4 is involved in the enhanced proliferation and survival of DUSP4-overexpressing cancer cells","volume":"528","author":"Ratsada","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31122","article-title":"G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells","volume":"117","author":"Cheriyath","year":"2007","journal-title":"J Clin Invest"},{"key":"B39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13045-018-0645-x","article-title":"The roles of metallothioneins in carcinogenesis","volume":"11","author":"Si","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.08.041","article-title":"Long noncoding RNA PURPL suppresses basal p53 levels and promotes tumorigenicity in colorectal cancer","volume":"20","author":"Li","year":"2017","journal-title":"Cell Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-487884","article-title":"Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma","volume":"122","author":"Kaiser","year":"2013","journal-title":"Blood"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-560862","article-title":"The sialyltransferase ST3GAL6 influences homing and survival in multiple myeloma","volume":"124","author":"Glavey","year":"2014","journal-title":"Blood"},{"key":"B43","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.yexcr.2015.01.006","article-title":"Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumor development in vivo","volume":"332","author":"Cheong","year":"2015","journal-title":"Exp Cell Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"IJH39","DOI":"10.2217\/ijh-2021-0017","article-title":"Adhesion molecules in multiple myeloma oncogenesis and targeted therapy","volume":"11","author":"Bou Zerdan","year":"2022","journal-title":"Int J Hematol Oncol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"E3","DOI":"10.1073\/pnas.1117374108","article-title":"Quantitative differences in CD45 expression unmask functions for CD45 in B-cell development, tolerance, and survival","volume":"109","author":"Zikherman","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1385\/IR:31:2:119","article-title":"CD19 function in central and peripheral B-cell development","volume":"31","author":"Del Nagro","year":"2005","journal-title":"Immunol Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.coviro.2016.12.001","article-title":"The role of CD27 in anti-viral T-cell immunity","volume":"22","author":"Grant","year":"2017","journal-title":"Curr Opin Virol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-014-8490-7","article-title":"Function of the tetraspanin molecule CD81 in B and T cells","volume":"58","author":"Levy","year":"2014","journal-title":"Immunol Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2007.12.006","article-title":"Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma","volume":"42","author":"Qiang","year":"2008","journal-title":"Bone"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500175049","article-title":"Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma","volume":"46","author":"Terpos","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-1687","article-title":"Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients","volume":"65","author":"Zannettino","year":"2005","journal-title":"Cancer Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.76","article-title":"The hypoxia target adrenomedullin is aberrantly expressed in multiple myeloma and promotes angiogenesis","volume":"27","author":"Kocemba","year":"2013","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M114.555789","article-title":"Neuron-derived neurotrophic factor functions as a novel modulator that enhances endothelial cell function and revascularization processes","volume":"289","author":"Ohashi","year":"2014","journal-title":"J Biol Chem"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.biocel.2008.01.022","article-title":"The endothelin axis in cancer","volume":"40","author":"Bagnato","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"B55","article-title":"Multiple myeloma with t(11;14): unique biology and evolving landscape","volume":"12","author":"Bal","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-008-9123-1","article-title":"Dual-specificity MAP kinase phosphatases (MKPs) and cancer","volume":"27","author":"Keyse","year":"2008","journal-title":"Cancer Metastasis Rev"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1158\/1538-7445.AM2018-2498","article-title":"Over-expression of dual-specificity phosphatase 4 (DUSP4) in multiple myeloma","volume":"78","author":"Xia","year":"2018","journal-title":"Cancer Res"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2012.02.021","article-title":"Downregulation of metallothionein 1F, a putative oncosuppressor, by loss of heterozygosity in colon cancer tissue","volume":"1822","author":"Yan","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B60","first-page":"55","article-title":"The relationship between metallothionein-1F (MT1F) gene and hepatocellular carcinoma","volume":"76","author":"Lu","year":"2003","journal-title":"Yale J Biol Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202200818","article-title":"Dynamic interplay between structural variations and 3D genome organization in pancreatic cancer","volume":"9","author":"Du","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2017.10.006","article-title":"Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer","volume":"147","author":"Chen","year":"2017","journal-title":"Gynecol Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.00289-22","article-title":"Context-Dependent Function of Long Noncoding RNA PURPL in Transcriptome Regulation during p53 Activation","volume":"42","author":"Hartford","year":"2022","journal-title":"Mol Cell Biol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1038\/s41419-021-04362-8","article-title":"PURPL represses autophagic cell death to promote cutaneous melanoma by modulating ULK1 phosphorylation","volume":"12","author":"Han","year":"2021","journal-title":"Cell Death Dis"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4998","DOI":"10.3892\/mmr.2019.10159","article-title":"Long noncoding RNA PURPL promotes cell proliferation in liver cancer by regulating p53","volume":"19","author":"Fu","year":"2019","journal-title":"Mol Med Rep"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2021.2017588","article-title":"Long non-coding RNA p53 upregulated regulator of p53 levels (PURPL) promotes the development of gastric cancer","volume":"13","author":"Cheng","year":"2022","journal-title":"Bioengineered"},{"key":"B67","unstructured":"2023"},{"key":"B68","unstructured":"2023"},{"key":"B69","unstructured":"IUPHAR\/PBS guide to PHARMACOLOGY"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02273-z","article-title":"Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial","volume":"29","author":"Crees","year":"2023","journal-title":"Nat Med"},{"key":"B72","unstructured":"2023"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081961","article-title":"A comprehensive review of the genomics of multiple myeloma: evolutionary trajectories, gene expression profiling, and emerging therapeutics","volume":"10","author":"Awada","year":"2021","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2831","article-title":"Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome","volume":"16","author":"Dickens","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.8545","article-title":"Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du My\u00e9lome","volume":"26","author":"Decaux","year":"2008","journal-title":"J Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11080","article-title":"Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008","journal-title":"Haematologica"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403823","article-title":"CD45 expression by bone marrow plasma cells in multiple myeloma: clinical and biological correlations","volume":"19","author":"Kumar","year":"2005","journal-title":"Leukemia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/cyto.b.21265","article-title":"Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma","volume":"90","author":"Flores-Montero","year":"2016","journal-title":"Cytometry B Clin Cytom"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.15.5.2600","article-title":"Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity","volume":"15","author":"Lukas","year":"1995","journal-title":"Mol Cell Biol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"249","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1182\/blood-2008-01-132134","article-title":"Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma","volume":"112","author":"Qiang","year":"2008","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discovery Today"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2014.442","article-title":"The repurposing drugs in oncology (ReDO) project","volume":"10","author":"Pantziarka","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat Rev Drug Discovery"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14771","article-title":"Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma","volume":"178","author":"Russignan","year":"2017","journal-title":"Br J Haematol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-016-2216-2","article-title":"Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity","volume":"142","author":"Vaiou","year":"2016","journal-title":"J Cancer Res Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15240","article-title":"In reply to Sch\u00e4fer et\u00a0al: new evidence on the role of endothelin-1 axis as a potential therapeutic target in multiple myeloma","volume":"184","author":"Russignan","year":"2019","journal-title":"Br J Haematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.3.806.806_806_812","article-title":"Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group","volume":"91","author":"Seidel","year":"1998","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694786","article-title":"Phase IB study of cabozantinib in patients with relapsed and\/or refractory multiple myeloma","volume":"127","author":"Lendvai","year":"2016","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V114.22.4954.4954","article-title":"A phase II trial of sunitinib (SU11248) in multiple myeloma","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v97.11.3349","article-title":"Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand","volume":"97","author":"Han","year":"2001","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.43","article-title":"A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function","volume":"25","author":"Vallet","year":"2011","journal-title":"Leukemia"},{"key":"B95","doi-asserted-by":"publisher","first-page":"20508","DOI":"10.1038\/s41598-020-77450-y","article-title":"Multiple myeloma hinders erythropoiesis and causes anemia owing to high levels of CCL3 in the bone marrow microenvironment","volume":"10","author":"Liu","year":"2020","journal-title":"Sci Rep"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2019-123891","article-title":"High level of CCL3 in the bone marrow microenvironment promotes anemia by suppressing the erythropoiesis differentiation of hematopoietic stem cells in myeloma","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1111\/head.13379","article-title":"History and review of anti-Calcitonin Gene-Related Peptide (CGRP) therapies: from translational research to treatment","volume":"58","author":"Tepper","year":"2018","journal-title":"Headache"},{"key":"B98","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br J Pharmacol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1993.1451","article-title":"Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma","volume":"192","author":"Kitamura","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.peptides.2020.170347","article-title":"Adrenomedullin - Current perspective on a peptide hormone with significant therapeutic potential","volume":"131","author":"Fischer","year":"2020","journal-title":"Peptides"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/s0167-0115(03)00037-5","article-title":"Adrenomedullin and cancer","volume":"112","author":"Zudaire","year":"2003","journal-title":"Regul Pept"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1390105\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T05:01:00Z","timestamp":1713243660000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1390105\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,16]]},"references-count":101,"alternative-id":["10.3389\/fonc.2024.1390105"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1390105","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,16]]},"article-number":"1390105"}}